Work

Supplemental Figures 9-12 from Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 9 The effect of treatment with c-myc inhibitor 10058-F4 in combination with niraparib Supplementary Figure 10 Screening of known MYC-inhibiting drugs. Supplementary Figure 11 Synergistic assessment of combination treatment with dinaciclib and PARPi on TNBC in vitro Supplementary Figure 12 Immunofluorescent analysis of breast cancer cells treated for 72-h with DMSO (control), niraparib (5 μM), dinaciclib (10 nM), or niraparib and dinaciclib (Combo).

DOI: 10.1158/0008-5472.22417124.v1

Authors: Jason. P.W. Carey, Cansu Karakas, Tuyen Bui, Xian Chen, Smruthi Vijayaraghavan, Yang Zhao, Jing Wang, Keith Mikule, Jennifer K. Litton, Kelly K. Hunt, Khandan Keyomarsi

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361256752

Cites:

Cited by:

Related to: 10